 Home > Medical News > Latest Medical News > Gan & Lee Pharmaceuticals opens first human trial of experimental drug GZR18

Gan & Lee Pharmaceuticals opens first human trial of experimental drug GZR18

 Last Update: 2022-04-28
 Source: Internet
 Author: User

Tags

garlic diabetes

glucagon uses

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

BEIJING AND BRIDGEWATER, NJ, USA, March 11, 2022 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co.

The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers, while the secondary objective is to determine the pharmacokinetic (PK) parameters of GZR18

references

[1].

Source: Gan & Lee Pharmaceuticals Co.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.